The broadly neutralizing antibody VH3810109, administered by a single IV infusion, displayed antiviral efficacy and was well tolerated in people with HIV naive to treatment.
In expanded multivariable analyses from ATLAS, ATLAS-2M, and FLAIR of PWH receiving LA CAB plus RPV, factors most predictive of confirmed virologic failure were preexisting rilpivirine resistance associated mutations and HIV-1 subtype A6/A1.
LA CAB + RPV was highly effective in US cohort of PWH virologically suppressed at regimen initiation and in a small number of PWH unsuppressed at initiation.
Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.
At Week 52, maintenance therapy with SC lenacapavir in combination with an optimized background regimen was associated with virologic suppression in 78% of heavily treatment–experienced persons with multidrug-resistant HIV infection.
Despite most survey participants reporting awareness of PrEP with approximately one half aware of LA PrEP, a minority had ever used PrEP and even fewer were currently using PrEP.
Post hoc analysis evaluated the effect of different islatravir doses on total lymphocyte and CD4+ T-cell and B-cell counts.
Efficacy advantage of long-acting CAB over FTC/TDF for HIV PrEP persisted 1 year after unblinding, with 3 new cases of INSTI mutations observed.
In models and simulations, islatravir 0.25 mg daily was predicted to have lymphocyte and CD4+ T-cell increases similar to standard ART.
Investigators state that data support effectiveness, safety, and persistence of BIC/FTC/TAF in treatment-naive and treatment-experienced PWH with a high prevalence of comorbidities at baseline.